Skip to main content
Premium Trial:

Request an Annual Quote

Quest, Health Discovery in Cancer Dx Licensing Deal

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics has licensed rights from Health Discovery Corp. and privately held firm Smart Personalized Medicine to develop laboratory tests that help determine appropriate breast cancer therapies.

The firms did not provide details on the licensed technologies. Under the terms of the agreements, Quest will pay health Discovery and SPM upfront licensing payments, development fees, and royalties on a per test basis.

Further terms were not disclosed.

Last year, Savannah, Ga.-based Health Discovery licensed to Quest rights to develop a new urine-based test for clinically significant prostate cancer.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.